High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
ID: 355867Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355867

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Aug 2, 2024, 12:00 AM UTC
  4. 4
    Due Feb 11, 2027, 12:00 AM UTC
Description

The National Institutes of Health (NIH) is offering a funding opportunity for high-priority research at the intersection of HIV and substance use through the National Institute on Drug Abuse (NIDA). This grant, identified as RFA-DA-25-024, aims to support innovative research projects that advance HIV/AIDS prevention, treatment, and outcomes for individuals using addictive substances, with a focus on addressing health disparities and enhancing perspectives from diverse populations. The total anticipated budget for this initiative is $3 million, with an expected number of 3-5 awards, and applications must be submitted between January 11, 2025, and February 12, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-DA-25-024.html
Aug 24, 2024, 2:22 AM UTC
The National Institutes of Health (NIH) is offering a funding opportunity for high-priority research at the intersection of HIV and substance use through the National Institute on Drug Abuse (NIDA). This grant (RFA-DA-25-024) focuses on projects that aim to advance HIV/AIDS research, prevention, treatment, and outcomes for individuals using addictive substances. Eligible applicants include various educational and nonprofit institutions, and for-profit organizations, as well as individuals from diverse backgrounds. Funded projects are expected to develop innovative research plans that tackle common health and social challenges, such as stigma and access to care, while enhancing perspectives from diverse populations. The total anticipated budget for this opportunity across multiple fiscal years is $3 million, with an expected number of 3-5 awards. Key application dates include a submission window opening on January 11, 2025, and an expiration date of February 12, 2027. The grant mandates the submission of a Plan for Enhancing Diverse Perspectives (PEDP), emphasizing inclusivity in recruitment and collaboration strategies. The review of applications will assess the overall impact, significance, rigor, and investigator expertise needed to address the focus areas effectively. This funding initiative reflects NIH’s commitment to addressing critical gaps in HIV-related care, particularly among marginalized populations.
Similar Opportunities
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, aimed at supporting innovative research that intersects HIV and substance use disorders. This grant opportunity encourages creative scientists to propose high-impact studies that lead to new therapies and preventative strategies for HIV among drug users, emphasizing originality and alignment with NIH’s HIV/AIDS research priorities. The program allows for clinical trial proposals with a funding ceiling of $700,000 per year for up to five years, with applications due by August 15, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Ex Vivo Models for Studies at the Intersection of HIV and Addictive Substance Use (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity for research focused on the neuroimmune mechanisms linking HIV and addictive substance use, specifically targeting HIV-associated neurological disorders (HAND). This grant aims to support innovative projects utilizing advanced ex vivo models derived from human induced pluripotent stem cells (hiPSC) to investigate how addictive substances influence HAND and HIV pathology, with an emphasis on cellular interactions, neurodegeneration, and inflammatory responses in the brain. The total funding available for this initiative is $2 million, and eligible applicants include educational institutions, nonprofits, government agencies, and foreign organizations. Applications are due by July 13, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-074.html.
Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)." This initiative aims to investigate the protein interaction networks in HIV-infected microglia and their implications for cellular signaling alterations associated with the coexistence of HIV and SUD, structured in a two-phase approach focusing on both quantitative analytics and in vivo models. The funding, anticipated to be approximately $2.5 million for FY 2026, will support 3-6 awards, with applications opening on July 14, 2025, and a submission deadline of August 14, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.